Lunes 9:30 – 20:00
Martes 10:00 – 20:00
Miercoles 10:00 – 20:00
Jueves 9:30 – 20:00
Viernes 9:30 – 16:00
Esta página web utiliza cookies propias, que pueden ser técnicas o analíticas, para asegurar el correcto funcionamiento de todos sus contenidos y hacer seguimiento del uso de los mismos. Accediendo a la política de cookies siempre podrás visualizar este banner que te permite configurar o rechazar las cookies. Puedes aceptar todas las cookies pulsando el botón “Aceptar” o configurarlas o rechazar su uso.
AceptarRechazar ×We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
Scientific publications: Oncothermia journal
Scientific publications: Oncothermia journal
Knowledge is a common good that must be shared and placed at the service of society. That is why scientific publications are an important dissemination tool. Paying special attention to treatments as particular as Oncothermia.
Oncological Nanotherapy or Oncothermia is a treatment known and accepted by many oncological specialists and institutions. And of which there are numerous clinical and observational studies in European and international hospitals, with proven and published results. All of them can be consulted in Oncothermia Journal. The articles can be found in electronic or printed version
More information
Also, if you need more information about clinical studies or other publications related to Oncothermia, you can visit the following link, where you will find an extensive list of them.
International Congress of Hyperthermic Oncology
International Congress of Hyperthermic Oncology
04/15/2016, New Orleans, United States
Hyperthermic Oncothermia is present internationally at congresses and conferences. Thus, in these scientific meetings, doctors give presentations to disseminate the results of clinical cases. Therefore, in this blog, we will inform about the events that take place, such as the following International Congress:
International Congress of Hyperthermic Oncology
Oncothermia is present internationally in congresses and conferences. In these scientific meetings doctors make presentations to disseminate the results of clinical cases. In this blog, we will inform about the events that take place.
On April 15, 2016 in New Orleans, United States, took place the International Congress of Hyperthermic Oncology (12th International Congress of Hyperthermic Oncology). In the United States, Hyperthermia is mainly applied in Oncology as a coadjuvant treatment. In the Congress presented results of the effect of Oncothermia with precise doses of radiotherapy (“Stereotaxis”) with excellent results.
Many interesting posters were presented. It is worthy of mention the presentations of: Dr. Michael Jackson of Canada and Dr. Heui-Kwan Lee of Korea.
Finally, if you want more information about the events related to Oncothermia treatment, you can visit the following website.
International Lungcancer Symposium
International Lungcancer Symposium
Oncothermia is an adjuvant method for the treatment of cancers, as in the case of Lung Cancer. It stands out for being a non-invasive method that can be combined with radiotherapy and chemotherapy.
Oncothermia is present internationally in congresses and conferences. In these scientific meetings doctors make presentations to disseminate the results of clinical cases.
2nd International Symposium on lung cancer
On April 17, 2016, in Budapest, the 2nd International Symposium on Lung Cancer took place (2nd International Lungcancer Symposium). The conference was organized in different sections. Professor Szasz directed the section: “Oncothermia in Advanced Lung Cancer”, where he presented his latest research and clinical results.
Clinical trials: Oncothermia and Cancer
Clinical trials: Oncothermia and Cancer.
Oncothermia is an active part of current medical research. There are several Clinical Trials, in patients with cancer, performed in different hospitals around the world.
Clinical trials are a basic tool for the development of drugs and medical devices, in order to improve the current treatment of diseases and develop health tools worldwide.
Clinicaltrials.gov is an internationally recognized web page, where researchers publish the latest clinical trials that are carried out in different hospitals around the world. Oncothermia is present on this website. We will inform you about the latest advances in Oncothermia and Cancer.
Clinical study of Oncothermia applied to a patient with malignant ascites
The clinical study “Oncothermia + intraperitoneal chemotherapy in malignant ascites: Phase II” (Local mEHT * + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT (OTMA-RII) of Prof. Pang, Clifford Hospital, Guangzhou, China) began to include patients in January 2014 and ended in March 2016. The research included two groups of 130 patients. The “experimental group” will be treated with: diet, Chinese herbal medicine and Oncothermia. Instead, the “control group” will be treated with chemotherapy.
We will be attentive to the conclusions of the study!
* Clinical trial “Oncothermia + intraperitoneal chemotherapy in malignant ascites: Phase II“
Oncothermia: its presence in the world
Oncothermia: its presence in the world
Oncothermia is a natural adjuvant and non-invasive method to treat cancer. It has now been distributed worldwide. It is present in 24 countries.
These are more than 180 facilities, including public hospitals and private clinics. It should be noted that more than 200,000 treatments are performed annually.
In Germany alone, Oncothermia equipment has been installed in 4 public hospitals, in addition to 80 private clinics. Among them the most relevant are:
In Barcelona
The Barcelona Oncothermia Unit is equipped with the latest generation EHZ-2000 model, placing it as a local and global benchmark.
If you need more information, you can consult the different Oncothermia facilities by country.
Oncothermia receives the patent as a “tumor vaccine”
Oncothermia receives the patent as a “tumor vaccine”
This treatment alerts our immune system by checking the cancer cells.
The Oncothermia EHY-2000 plus device received the patent, US 20150217099 A1 in August 2015, describing this treatment as “a tumor vaccine”. It refers to “a vaccine” because it stimulates the immune system and radiofrequency promotes apoptosis or cell death of tumor cells.
Procedure of action of the “vaccine”
The applied technique is called Modulated Electro-Hyperthermia (mEHT). The cancer cells in our body when treated with mEHT produce “heat shock proteins” when they are heated. This treatment alerts our immune system by checking the cancer cells. In this way, these cells are recognized by our immune system and eliminate them.
We all have approximately 1000 cancer cells that circulate in our body every day. Those with a weak immune system can develop a tumor.
In conclusion
For patients diagnosed with cancer, Oncothermia is an excellent option for immunotherapy to complement conventional treatments: surgery, chemotherapy or radiotherapy, in an integrative oncology framework.
You can obtain more information about the operation of Oncothermia for treatments in cancer patients through this link.
Oncothermia versus hyperthermia: cellular effects in complementary treatments of cancer
Oncothermia is based on the Hyperthermia method, frequently used for cancer treatments. But unlike conventional Hyperthermia, Oncothermia, in addition to producing an absolute increase in the temperature of the deep tissue layers, also combines the action of the modulated electric field, with a carrier frequency of 13.56MHz, which is generated by two electrodes assets.
Selective capacity of Oncothermia with respect to Hyperthermia
Microbiological studies have shown that cancerous tissues have a greater conductivity in relation to healthy tissues, due to metabolic differences. It is for this reason that the electric field tends to flow preferentially in the malignant tumor tissue, selecting the cells to be treated.
The natural activity of malignant cells is inhibited, dying by apoptosis, that is, by a natural process of cell death induced by the immune system without overloading toxins in the body; unlike necrosis, pathological cell death, produced in conventional hyperthermia.
Conclusion
While conventional hyperthermia disperses heat, oncothermia focuses on the tumor, captures cancer cells by the frequency they emit, focusing it and making it more effective.
If you wish, you can find more information about Oncotermia treatment on our website.
Oncothermia in combination with Radiotherapy exerts a radiosensitizing effect in lung cancer.
The sensitivity of tumors to radiotherapy and chemotherapy is increased by Oncothermia.
Oncothermia, also known as electro-hyperthermia, is a new treatment modality that allows for increased sensitivity to other treatments. It has been developed to overcome the problems of traditional hyperthermia by targeting malignant tissues.
A study was published in 2015 in the journal Experimental and Therapeutic Medicine. It reports the outcome of combined oncothermia and RT in a 75-year-old patient with stage IIIB non-small-cell lung cancer (NSCLC).
Due to the advanced age and the performance status of the patient, the combination of systemic chemotherapy and RT was deemed infeasible. Therefore, the patient instead decided to undergo oncothermia concurrently with definitive RT.
The RT was administered at a dose of 64.8 Gy in 36 fractions using a three-dimensional conformal plan technique. In this case, Oncothermia was started concomitantly with RT. And was performed for 60 min per session, two sessions per week, for a total of 12 sessions.
In conclusion, the present case report suggests that oncothermia combined with RT has former possessing radiosensitizing potential and no additional toxicities. May be it is a promising alternative for advanced-age and/or frail patients with locally advanced NSCLC.
In addition, you can find more information about lung cancer on our website.
Stage IV Kidney Cancer treated by Oncothermia and herbs
Stage IV Kidney Cancer (Wilms Tumor) treated by Oncothermia and herbs
[message_box title=”Wilms tumour is the most common cause of kidney cancer in childhood and adolescence.” color=”red”]It also carries a mortality rate of 7-8 in one million. The 5-year survival rate for kidney cancer is 77.2 – 87.5%. When Wilms tumour progresses, radiotherapy and chemotherapy are conventionally used as the only treatments.[/message_box]
Clinical case
A 17-year-old Korean woman was treated from October 25, 2014, until July 22, 2015 with an integrating medical treatment, in order to control the extent of her illness.
The integrative medical treatment included: oncothermia, thymosin-α1 and phytotherapy. Phytotherapy was administered in 8 ml. of inhalation of Soram nebulizer solution qd, Soramdan S 8 g po, Hangamdan S 1 g po, tid, Cheongjangtang 10-30 ml, and Spiam HC 8 g po. She received Oncothermia (2-3 times a week) and 1.6 mg of treatment with thymosin-α1 (Zadaxin) i.m.
Result
According to the result of the CT on July 15, 2015, the liver metastasis was no longer seen, while the lung metastasis remained stable without tumor progression.
Conclusion
In patterns of Wilms tumor progression after surgery and chemotherapy, integrative medical treatment can be significant for disease control.
Reference
Lee D, Kim SS, Seong S, Cho W, Yu H. Stage IV Wilms Tumor Treated by Korean Medicine, Hyperthermia and Thymosin-α1: A Case Report. Case Rep Oncol. 2016 Feb 20;9(1):119-25. doi: 10.1159/000443724.
If you wish, you can find more information about clinical cases treated with Oncotermia on our website.
Transcranial Oncothermia in patients with relapsed high-grade gliomas
Transcranial Oncothermia in patients with relapsed high-grade gliomas
Experimental data and retrospective studies suggest potential effects
Dr. Wismeth’s Team of the Department of Neurology of the University of Regensburg, Germany, published in the journal J Neurooncol (J Neurooncol, 2010 Jul; 98 (3): 395-405) the results of the joint use of Oncothermia and chemotherapy used as salvage treatment in the relapse of patients with high-grade gliomas.
Experimental data and retrospective studies suggest potential effects. However, no prospective clinical results are available. A single-center prospective non-controlled single-arm Phase I trial was performed. Main inclusion criteria were recurrent high-grade glioma WHO Grade III or IV, age 18-70, and Karnofsky performance score > or = 70.
Primary endpoints were dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) with the combined regimen. Groups of 3 or 4 patients were treated 2-5 times a week in a dose-escalation scheme with Oncothermia. Alkylating chemotherapy (ACNU, nimustin) was administered at a dose of 90 mg/m(2) on day 1 of 42 days for up to six cycles or until tumor progression (PD) or DLT occurred. Fifteen patients with high-grade gliomas were included.
Relevant toxicities were local pain and increased focal neurological signs or intracranial pressure. No DLT occurred. In some patients, the administration of mannitol during EHT or long-term use of corticosteroids was necessary to resolve symptoms.
Results
Oncothermia in combination with chemotherapy is tolerable in patients with relapse of high-grade gliomas. A Phase II trial targeting treatment effects is warranted on the basis of the results raised in this trial.
If you wish, you can find more information about clinical cases treated with Oncotermia on our website.